Daunorubicin
An anthracycline antineoplastic drug.
General information
Daunorubicin on DrugBank
Daunorubicin on PubChem
Marketed as
CERUBIDIN; CERUBIDINE; DAUNOBLASTIN; DAUNOBLASTINA; DAUNORRUBICINA; DAUNORUBICIN HYDROCHLORIDE; DAUNOXOME; MAXIDAUNO
C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
Small molecule |
in silico | 42.78 | Apr/30/2020 | |
|
Repurposing novel therapeutic candidate drugs for coronavirus disease-19 based on protein-protein interaction network analysis
Small molecule In silico Screening |
in silico (protein-protein interaction network analysis) | 2.31 | Computationally predicted to be efficacious in COVID-19 treatment based on protein-protein interaction network analysis. |
Mar/12/2021 |
AI-suggested references
| Link | Publication date |
|---|---|
|
Predictive modeling and therapeutic repurposing of natural compounds against the receptor-binding domain of SARS-CoV-2.
|
Jan/03/2022 |
